Literature DB >> 2876505

Somatostatin receptors.

M J Lewin.   

Abstract

More insight into the biochemical structure and operation of the somatostatin receptor(s) has been gained in recent years from several approaches. The minimal active structure of the receptor(s) has been identified, and active minisomatostatins have been synthesized. High-affinity binding sites (KDS ranging from 0.1 to 1 nM) have been demonstrated in brain and peripheral organs. In pancreas, stomach, and intestine additional low-affinity sites (or states) have been also suggested Furthermore, cytosolic receptors might be present. Binding affinities of synthetic minisomatostatins, somatostatin-14 and somatostatin-28, show different tissue specificities, suggesting the existence of different receptor subtypes. Two possible interactions of somatostatin with stimulus-secretion coupling in secretory cells have been suggested: a direct activation of the GTP-dependent inhibitory subunit of adenylate cyclase and a distal activation of cytosolic phosphoprotein phosphatases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876505     DOI: 10.3109/00365528609087430

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  3 in total

Review 1.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

2.  The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease.

Authors:  Gerasimos E Krassas; Themistoklis Tzotzas; Konstantinos Papazisis; Kaliopi Pazaitou-Panayiotou; Kostas Boboridis
Journal:  Clin Ophthalmol       Date:  2007-09

3.  Effects of PGE2, misoprostol, and enprostil on guinea pig enterocyte adenylate cyclase. Clinical implications.

Authors:  J M Pawlotsky; P Ruszniewski; F Reyl-Desmars; M Bourgeois; M J Lewin
Journal:  Dig Dis Sci       Date:  1993-02       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.